A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Flemington, Fortgang,Fontham, Friedlander, Franklin
Erik K. Flemington, Ph.D.

Professor of Pathology
TCC Program Member
(504) 988-1167
1430 Tulane Ave., Box SL-79, New Orleans, LA 70112-2699
eflemin@tulane.edu
Laboratory homepage
Homepage on the Pathology website:
http://www.som.tulane.edu/departments/pathology/faculty/Fleming/Fleming.html



Biographical Narrative:

Dr. Flemington received his B.S. degree in Chemical Engineering from Michigan Technological University. He carried out his doctoral studies in Dr. Prescott Deininger's laboratory and received a Ph.D. in Biochemistry and Molecular Biology from the Louisiana State University in New Orleans in 1987. His post-doctoral work was carried out in Dr. Sam Speck's laboratory at the Dana Farber Cancer Institute in Boston where he investigated the transcriptional mechanisms involved in the Epstein Barr virus (EBV) reactivation switch. In 1991, Dr. Flemington was appointed as an Instructor of Pathology at Harvard University and in 1995, he was appointed as Assistant Professor in the department of Medicine at Harvard Medical School. In 2000, he joined the Tulane Cancer Center as an Associate Professor in the department of Pathology where he continues his work investigating transcriptional control mechanisms involved in cell cycle regulation and his work on mechanisms governing the interplay between EBV lytic replication and the cell cycle.


There are currently two major efforts in Dr. Flemington's laboratory. First, Dr. Flemington is continuing a long-standing interest in cell cycle regulation during the lytic replication phase of the human DNA tumor virus, Epstein Barr virus (EBV). His lab previously discovered that although the EBV latency associated gene expression program promotes cell cycle progression and tumorgenesis, the lytic replication cycle actively blocks cell cycle progression and consequently, has anti-tumorgenic properties. Dr. Flemington's lab is currently addressing the mechanisms utilized by EBV to block cell cycle progression during lytic replication. His lab is also carrying out screening of chemical libraries to identify new compounds that activate the EBV lytic cycle in an attempt to identify new anti-tumor candidates. The other major effort ongoing in Dr. Flemington's lab is fundamental cell cycle control studies. This effort focuses on the transcription factor, E2F, which plays a key role in regulating cell cycle progression. His recent studies have shown that a new 450 kdal E2F interacting protein, referred to as TRRAP, inhibits E2F mediated G1-S phase transition. As such, TRRAP may play a tumor suppressor like role in vivo. His lab is currently addressing the mechanisms through which the interaction between TRRAP and E2F influences E2F activity and cell cycle progression.



Selected Publications:
  • Rodriguez A, Flemington EK. Transfection mediated cell cycle signaling. Anal Biochem 272: 171-181 (1999)
  • Rodriguez A, Armstrong M, Dwyer D, Flemington EK. Genetic dissection of cell growth arrest functions mediated by the Epstein-Barr virus lytic gene product, Zta. J Virol 73: 9029-9038 (1999)
  • Campanero MR, Armstrong M, Flemington EK. Distinct cellular factors regulate the c-myb promoter through its E2F element. Mol Cell Biol 19: 8442-8450 (1999)
  • Campanero MR, Armstrong M, Flemington EK. CpG methylation as a novel mechanism for the regulation of E2F activity. Proc Natl Acad Sci USA 97: 6481-8486 (2000)
  • Rodriguez A, Jung EJ, Flemington EK. Cell cycle analysis of Epstein Barr virus infected cells following treatment with lytic cycle inducing agents. J Virol 75: 4482-4489 (2001)
  • Flemington EK Herpesviral lytic replication and the cell cycle: Arresting new developments. J Virol 75: 4475-4481 (2001)
  • Rodriguez A, Jung EJ, Yin Q, Cayrol, C, Flemington EK. Role of c-myc regulation in Zta mediated induction of the cyclin dependent kinase inhibitors, p21 and p27, and cell growth arrest. Virology 284:159-169 (2001)
  • Ryu, H, Lee, J, Olofsson, BA, Mwidau, A, Deodoglu, A, Escudero, M, Flemington EK, Azizkhan-Clifford, J, Ferrante, RJ, Ratan, RR. Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc Natl Acad Sci 100:4281-4285 (2003)
  • Lin, Z, Yin, Q, Flemington EK. Identification of a Negative Regulatory Element in the Epstein-Barr virus (EBV) Zta Transactivation Domain that is Regulated by the Cell Cycle Control Factors, c-Myc and E2F1. J Virol 78:11962-11971 (2004)

Back to the top

Ilana S. Fortgang, M.D.

Assistant Professor of Pediatrics, Section of Gastroenterology
TCC Contributing Member
(504) 988-0297
1430 Tulane Ave., Box SL-37, New Orleans, LA 70112-2699
fortgang@tulane.edu

Biographical Narrative:

Ulcerative colitis and Crohn disease are the inflammatory bowel diseases (IBD) characterized by repeated bouts of acute intestinal mucosal injury and epithelial cell destruction. Patients with IBD harbor an increased risk of colon cancer and develop this malignancy at much younger ages than do those in the general population. Although the precise etiology of IBD is not yet known, it is appreciated that susceptible individuals respond in a dysregulated manner to enteric luminal antigens. This reaction is significant for a pathological influx of inflammatory cells to the damaged tissue, resulting in a predominant and enduring surge of proinflammatory cytokines, including tumor necrosis factor (TNF). As well, and despite its name, increased levels of TNF have been found in the setting of numerous carcinomas. The goal of Dr. Fortgang's current research is to define the specific role of tumor necrosis factor receptors (TNFRs) in neoplastic transformation associated with chronic inflammation. Specific emphasis is to be placed on elucidating the downstream pathways activated over the course of tumorigenesis. The overall hypothesis is that loss of TNFR1 but not of TNF or TNFR2 confers increased vulnerability to invasive carcinoma. Her team will explore the discrete roles of TNF and TNFRs and their signal transduction pathways utilizing the well-characterized AOM/DSS model of chronic colitis and tumorigenesis. These studies have potential direct relevance to the treatment of human cancers because they will identify novel therapeutic targets and define their mechanisms of regulation, crucial steps in the process of determining and designing small molecules to modulate activity in vivo.

Selected Publications:

  • Fortgang I, Srivastav S, Baskin GB, Schumacher PM, Levy LS. Retrospective analysis of clinical and laboratory factors associated with lymphoma in simian AIDS. Leukemia & Lymphoma, 45:161-169, 2004.
  • Bellows C, Belafsky P, Fortgang IS, Beech DJ. Melanoma in African-Americans: trends in biological behavior and clinical characteristics over two decades. J. Surg Oncology Suppl., 78(1): 10-16, 2001.
  • Fortgang IS, Baskin GB, Ruff K, Levy LS. Pathobiology of simian-AIDS-associated lymphoma: the Tulane Regional Primate Research Center (TNPRC) experience. Recent Res Devel Virol, 2(2001): 455-470, 2001.
  • Fortgang IS, Rege T, Baskin GB, Murphy-Corb M, Levy LS. Variation in simian immunodeficiency virus env V1 region in simian AIDS-associated lymphoma. AIDS Res and Hum Retroviruses, 17: 459-465, 2001.
  • Fortgang IS, Didier PJ, Levy LS. B-cell leukemia in a rhesus macaque (Macaca mulatta) infected with simian immunodeficiency virus. Leukemia and Lymphoma, 37: 657-662, 2000.
  • Habis A, Baskin G, Simpson L, Fortgang I, Murphey-Corb M, Levy LS. Rhesus lymphocryptovirus infection during the progressions of SAIDS and SAIDS-associated lymphoma in the rhesus macaque. AIDS Res and Hum Retroviruses, 16: 163-171, 2000.

Back to the top

Elizabeth T.H. Fontham
Dean

Positions and Employment

  • 1968-1970        Research Assistant, Cancer Research Laboratory, University of Virginia Medical School,Charlottesville
  • 1977-1979        Teaching Assistant, Tulane University School of Public Health and Tropical Medicine
  • 1979-1980        Research Associate, Dept. of Pathology, Louisiana State University Medical Center
  • 1980-1984        Instructor, Dept. of Pathology, Louisiana State University Medical Center
  • 1984-1989        Assistant Professor, Dept. of Pathology, Louisiana State University Medical Center
  • 1989-1996        Associate Professor, Dept. of Pathology, Louisiana Sate University Medical Center
  • 1990-1997        Assistant Editor-Cancer Epidemiology, Biomarkers and Prevention
  • 1996-present    Professor, Dept. of Pathology, Louisiana State University Medical Center
  • 1996-present    Associate Director, Stanley S. Scott Cancer Center
  • 1986-2005        Adjunct Faculty (Professor), School of Public Health and Tropical Medicine, Tulane University
  • 1992-present    Senior Epidemiology Consultant-Office of Public Health, Section of Environmental Epidemiology
  • 1998- 2003       Professor and Chairman, Dept. Public Health & Preventive Medicine, LSUMC School of Medicine
  • 2004-present     Dean, School of Public Health, LSUHSC

Selected Publications

  • Fontham, ETH.  Epidemiology of cancer of the pancreas. In: Cancer of the Digestive Tract, Correa P, Haenszel W (eds.).Martinus Nijhoff, The Hague, 1982, pp.243-259.
  • Correa P, Pickle LW, Fontham ETH, Lin Y, Haenszel W.  Passive smoking and lung cancer. Lancet, Sept., 1983, pp 595-597.
  • Correa P, Fontham ETH, Pickle LW, Chen VW, Lin Y, Haenszel W.  Dietary determinants of gastric cancer in south Louisiana. JNCI 75:645-653, 1985.
  • Fontham ETH, Correa P, Rodriguez E, Lin Y. Validation of smoking history with the micronuclei test.  In: Banbury Report 23: Mechanisms in Tobacco Carcinogenesis, Cold Spring Harbor Laboratory, 1986, pp.113-119.
  • Fontham ETH, Zavala D, Correa P, Rodriguez E, Hunter F, Haenszel W, Tannenbaum SR.  Diet and chronic atrophic gastritis. JNCI 76:621-627, 1986.
  • Schiffmann MH, Pickle LW, Fontham ETH, Zahm SH, Meli J, Falk R, Correa P, Fraumeni JF Jr.  A case-control study of diet and mesothelioma. Cancer Res 48:2911-2915, 1988.
  • Falk RT, Pickle LW, Fontham ETH, Correa P, Fraumeni J.  Lifestyle and pancreatic cancer in Louisiana: A case-control study. Am J Epidemiol 128:324-336, 1988.
  • Fontham ETH, Haenszel W, Pickle LW, Correa  P, Lin Y, Falk RT.  Dietary vitamins A and C and lung cancer risk in Louisiana.  Cancer 62:2267-2273, 1988.
  • Fontham ETH, Correa P. Epidemiology of pancreatic cancer.  Surgical Clinics of North America 63(3):551-567, 1989.
  • Fontham ETH.  Protective dietary factors and lung cancer. Int J Epidemiol 19(3)(Suppl 1): 33-42, 1990.
  • Fontham ETH, Correa P, Wu-Williams A, Reynold P, Greenberg RS, Buffler PA, Chen VW, Boyd P, Alterman T, Austin DF, Liff J, Greenberg SD.  Lung cancer in non-smoking women: a multicenter case-control study. Cancer Epidemiology, Biomarkers and Prevention 1:35-43, 1991.
  • De Stefani E, Fierro L, Correa P, Fontham ETH, Chen V, Zavala.  The effect of alcohol on the risk of lung cancer in Uruguay. Cancer Epidemiol, Biomarkers & Prev 2(1):21-32, 1993.
  • Fontham E, Correa P. The epidemiologic approach to the study of protease inhibitors.  In: Protease Inhibitors as Cancer Chemoprevention Agents, W. Troll and A.R. Kennedy, eds., 1993, pp.1-8.
  • Fontham ETH, Correa P, Reynolds P, Wu-Williams A, Buffler PA, Greenberg RS, Chen VW, Alterman T, Boyd P, Austin DF, Liff J. Environmental tobacco smoke and lung cancer in nonsmoking women: A multicenter study. JAMA, 271(22): 1752-1759, 1994.
  • Fontham ETH. Vitamin C, vitamin C-rich foods, and cancer: Epidemiologic and clinical studies. In: Natural Antioxidants in Human Health and Disease. Balz Frei, Ed. Academic Press, Inc., Orlando, FL., pp. 157-197, 1994.
  • Correa P, Fontham ETH, Ruiz B, Malcom GT, Hunter FM, Zavala D.  Gastric juice ascorbic acid after intravenous injection: Effect of ethnicity, pH, and Helicobacter pylori infection. JNCI 87 (1):  52-53, January 4, 1995.
  • Fontham ETH, Ruiz B, Perez A, Hunter F and Correa P.  Determinants of Helicobacter pylori infection and chronic gastritis. Amer J of Gastro 90 (7): 1094-1101, 1995.
  • Wu-Williams A, Fontham ETH, Reynolds P, Greenberg P, Buffler PA, Liff J, Boyd P, Henderson B, Correa P.  Previous lung disease and risk of lung cancer among lifetime nonsmoking women in the U.S. Am J Epidemiol 141:1023-32, 1995.
  • Fontham ETH, Malcom GT, Singh VN, Ruiz B, Schmidt B, Correa P. Effects of Beta-carotene supplementation on serum a-tocopherol concentration. Cancer Epid Biomarkers and Prev 4: 801 - 803, 1995.
  • Reynolds P, Fontham ETH. Passive Smoking and Lung Cancer. Annals of Medicine 27: 633-640,1995.
  • Wu AH, Fontham ETH, Reynolds P, Greenberg RS, Buffler P, Liff J, Boyd P, Correa P.  Family History of Cancer and Risk of Lung Cancer among Lifetime Nonsmoking Women in the United States. Am J Epidemiol 143 (6): 535-542, 1996.
  • Fontham E. Diet and lung cancer. (Editorial) Cancer Causes Control 8(6): 819-820, 1997
  • Correa P, Malcom G, Schmidt B, Fontham E, Ruiz B, Bravo JC, Bravo LE, Zarama G, Realpe JL. Antioxidant Micronutrients and Gastric Cancer. Aliment Pharmacol Therl2(Suppl 1):73-82, 1998.
  • Gong C, Mera R, Bravo JC, Ruiz B, Fontham ETH, Correa P, Hunt JD.  KRAS mutations predict progression of preneoplastic gastric lesions. Cancer Epid Biomarkers Prev 8:167-171, 1999.
  • Heath C and Fontham ETH.  Cancer Etiology. In The American Cancer Society's Clinical Oncology. Lenhard RE, Osteen RT and Gansler T, Eds. Blackwell Science, Inc. Maiden MA, pp. 37-54,2000.
  • Correa P, Fontham ETH, Bravo JC, Bravo LE, Ruiz B, Malcom GT, Realpe JL, Li D, Johnson WD, Mera R. Chemoprevention of Gastric Dysplasia: Effect of Anti-Oxidants and Anti-­Helicobacter Therapy. JNCI 92(23): 1881-1888, 2000.
  • Hunt JD, Mera R, Strimas A, Gillespie AT, Ruiz B, Correa P, Fontham ETH.  KRAS Mutations are not Predictive for Progression of Preneoplastic Gastric Lesions. Cancer Epidemiology Biomarkers and Prevention 10:79-80, 2001
  • The Surgeon General’s Report:  Women and Smoking. Contributing author Fontham ETH:  Environmental Tobacco Smoke and Lung Cancer (Cpt  3) USDHHS, Public Health Science.  Rockville, MD.  2001, pp 343-350.
  • Fontham ETH, Prevention of Upper Gastrointestinal Tract Cancers.  In  Prevention Nutrition.  The Guide for  Health Professionals.   A. Bendich and R.J. Decklbaum (Ed) Humana  Press, Totowa ND, 2001, pp 21 – 45.
  • Fontham ETH.  Cancers of the Lung and Pancreas in Acadiana.  The Hereditary Healing Project. http://www.lsuhsc.edu/Centers/Genetics, 2001.
  • Hunt JD, Strimus A, Martin JE, Eyer M, Haddican M, Luckett BG, Ruiz B, Axelrad TW, Backes WL, Fontham ETH.  Differences in KRAS <utation Spectrum in Lung Cancer Cases between African Americans and Caucasians after Occupational or Environmental Exposure to Known Carcinogens.Cancer Epidemiol Biomarkers Prev 11:1405-1412, 2002.
  • Bedoya A, Garay J, Sanzon F, Bravo LE, Bravo JC, Correa H, Craver R, Fontham E,Du X, Correa P.  Histopathology of gastritis in Helicobacter pylori infected children at high- vs low-gastric cancer risk. Human Pathology 34(3), 206-213, 2003.
  • Buffler P, Doll R, Fontham E, Gao Y-T, Gupta P, Hackshaw A, Matos E, Samet J, Thun M, Straif K, Vineis P. Wichmann H-E, Wu A, Saridze D. (Members of the IARC Working Group)  Environmental tobacco smoke and lung cancer  (letter) British Medical Journal, 2003.  http://www.bmj.com/cgi/eletters/326/7398/1057
  • Wu X-C, Chen V, Ruiz B, Andrews P, Correa C, Schmidt BA, Fontham ETH.  Patterns of treatment for ductal carcinoma in situ of the breast in Louisiana 1988-1999.  J. La. State Med. Soc. 155, 206-213, 2003.
  • Fishbach LA, Correa P, Feldman M, Fontham ET, Priest E, Goodman K, Jain R.  Increased reflux symptoms after calcium carbonate supplementation and successful anti-Helicobacter pylori treatment.  Digestive Diseases and Sciences 48(8), 1487-1494, 2003
  • Bravo LE, Mera R, Reina JC, Pradilla A, Alzate A, Fontham E, Correa P.  Impact of Helicobacter infection on growth of children: A prospective cohort study.  Journal of Pediatric Gastroenterology and Nutrition 37:614:619, 2003.
  • Brennan PJ, Buffler PA, Reynolds PR, WuA, Wichmann H-E, Agudo A, Pershagan G, Jockel K-H, Benhamou S, Greenberg RS, Merletti F, Winck C, Fontham ETH, Kreuzer M, Darby SC, Forastiere F, Simonato L, Boffetta P.  Secondhand smoke exposure in adulthood and risk of lung cancer among never-smokers.  A pooled analysis of two large studies.  International Journal of Cancer, 109(1): 125-131, 2004
  • Vineis P, Alavanja M, Buffler P, Fontham E, Gao YT, Gupta PC, Hackshaw A, Matos E, Peto R, Samet J, Sitas F, Straif K, Thun MJ, Wichmann HE, Wu AH, Zaridze D, Doll R.  Tobacco and cancer: recent epidemiologic evidence. J Natl Cancer Insti, 96:99-106, 2004
  • Contributing author: Fontham ETH.  IARC Monographs on the Evaluation of Carcinogenic Risks to Humans.  Volume 83.  Tobacco Smoke and Involuntary Smoking.  International Agency for Research on Cancer.  Lyon FR 2004
  • Camargo MC, Yepez MC, Ceron C, Guerrero N, Bravo LE, Correa PC, Fontham ETH.  Age at acquisition of Helicobacter pylori infection:  comparison of two areas with contrasting risk of gastric cancer.  Helicobacter 9(3), 262-270, 2004.
  • Du JX, Watkins T, Bravo LE, Fontham ETH, Camargo MC, Correa P, Mera R.  13-C urea Breath Test for Helicobacter pylori inYoung Children:Cut-off Point Determination by Finite Mixture Model.Statistics in Medicine 23(13) 2049-2060, 2004
  • Correa P, Fontham ETH, Bravo LE, Mera R.  Antioxidant supplements for prevention of gastrointestinal cancer.  The Lancet 365: 470-472, 2005.
  • Mera R, Fontham ETH, Bravo LE, Bravo JC, Piazuelo B, Camargo MC, Correa P.  Long term follow-up of patients treated for Helicobacter pylori infection.  Gut.  54(11):1536-40, 2005.
  • Fontham ETH, Correa P, Mera R, Bravo LE, Bravo JC, Piazuelo MB, Camargo MC.  Duration of exposure, a neglected factor in chemoprevention trials.  Cancer Epidemiol Biomarkers Prev. 14(11), 2005.
  • Mera, R., Correa, P, Fontham E, Reina JC, Pradilla A, Alzate ABravo, LE.  Effects of a new H. pylori infection on height and weight in Colombian Children.  Ann Epidemiol.  16: 347-351, 2006
  • Zabaleta J, Camargo MC, Piazuelo MB, Fontham E, Schneider B, Sicinski L, Ferrante W, Balart L,  Correa P, Ochoa AC.  Association of polymorphisms of interleukin-1 genetic polymorphisms with gastric precancerous lesions in African Americans and Caucasians. Am J Gastroenterology 101(1):163-171, 2006
  • Schroeder JC, Benson J, Su J, Mishel M, Smith G, Fontham ETH, Mohler J.  The North Carolina-Louisiana Prostate
    Cancer Project (PCaP):  A multidisciplinary population-based cohort study of racial differences in prostate cancer outcomes.  Prostate 66(11):1162-1176, 2006
  • Byers T, Barrera E, Fontham E, Newman L, Runowicz C, Sener SF, Thun M, Winborn S, Wender RC. A midpoint assessment of the ACS challenge goal to halve the U.S. cancer mortality rates between the years 1990 and 2015.  Cancer 107:396-405, 2006

Back to the top

Paul L. Friedlander, M.D.

Clinical Associate Professor of Otolaryngology
TCC Associate Member
(504) 988-1028
1430 Tulane Ave., Box SL-59, New Orleans, LA 70112-2699
pfriedla@tulane.edu

 

 

Biographical Narrative:

Dr. Friedlander received his B.S. in biology from Georgetown University and his M.D. from LSU (New Orleans). Following medical school, he completed a two-year general surgery residency at George Washington University, an otolaryngology residency at LSU (New Orleans), and a head and neck surgical oncology fellowship at Memorial Sloan-Kettering Cancer Center. In 1997, he joined the faculty at LSU, where the majority of his effort was in translational research in head and neck cancers. He established the head and neck tumor bank there, which was responsible for collecting clinical information and samples on 250 patients with head and neck cancers. He also participated in translaitonal research involving the use of modified adenoviruses in targeting head and neck cancer as well as immunomodulation of head and neck cancer using the CD40 ligand protein. He is currently investigating the possible role of the Hepatitis C virus as a cofactor in the development of head and neck cancer.

Selected Publications:

  • Nobles J, Hagan J, Wold C, Fazekas-May M, Gilbert J, Friedlander PL. Outcome analysis of patients with squamous cell carcinoma of the head and neck and hepatitis C. Laryngoscope, 115(10):1882-86, 2005.
  • Nobles J, Wold C, Fazekas-May MA, Friedlander PL. The incidence and epidemiology of hepatitis C virus (HCV) in patients with squamous cell carcinoma of the head and neck (SCCHN). Laryngoscope, 114 (112): 2119-22, 2004.
  • Lanson NA, Friedlander PL, Schwarzenberger P, Kolls JK, Wang G. Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promotor causing tumor-selective tumorlysis. Cancer Research, 63(22): 7936-41, 2003.
  • Friedlander PL, Delaune CL, Abadie J, Toups M, LaCour J, Marrero L, Zhong Q, Kolls J. Immunoprotective effect of CD40 ligand gene therapy in malignant mesothelioma and squamous cell carcinoma. American Journal of Respiratory Cell and Molecular Biology, 29(3): 321-330, 2003.
  • Lalonde ES, Beyers G, Friedlander PL, Kolls J. Efficacy of transfection rates on head and neck squamous cell cancer by a novel adenovirus: an in vitro and in vivo study. Head and Neck, 24(12): 1038-1046, 2002.

Back to the top

dfranklinDavid S. Franklin, Ph.D.

Associate Professor of Biochemistry
TCC Program Member
(504) 988-8868, (504) 988-2739 Fax
1430 Tulane Ave., Box SL-43, New Orleans, LA 70112-2699
franklin@tulane.edu

 

 

Biographical Narrative:

Dr. Franklin received his Ph.D. in 1994 from Louisiana State University Medical Center (now LSUHSC). His research interests involve the human cancer syndrome multiple endocrine neoplasia (MEN). Using both tissue culture and in vivo mouse model systems, his lab studies the tumor suppressor MEN1 and proto-oncogene RET, whose mutations predispose patients to develop MEN tumors. Specifically, how do the MEN1 and RET gene products mediate normal cell cycle regulation? What are the effects of MEN tumor-specific mutations on the normal processes? In addition, the Franklin lab is involved in assessing the potential use of the Reishi mushroom as a complementary and alternative medicine in mouse models for breast and colon cancer.

Selected Publications:

  • Joshi PP, Kulkarni MV, Yu BK, Smith KR, Norton DL, Van Veelen W, Hoppener JWM, Franklin DS. Simultaneous down regulation of CDK inhibitors p18INK4c and p27KIP1 is required for MEN2A-RET mediated mitogenesis. Oncogene, 26:554-570, 2007.
  • Paris M, Wang WH, Franklin DS, Andrisani OM. The homeodomain transcription factor Phox2a, via cAMP-mediated activation, induces p27KIP1 transcription, coordinating neural progenitor cell cycle exit and differentiation. Mol Cell Biol, 26(23): 8826-8839, 2006.
  • Damo LA, Snyder PW, Franklin DS. Tumorigenesis in p27/p53- and p18/p53-double null mice: functional collaboration between the pRb and p53 pathways. Mol Carcinogenesis, 42:109, 2005.
  • Yuan Y, Shen H, Franklin DS, Scadden DT, Cheng, T. In vivo self-renewing divisions of hematopoietic stem cells are increased in the absence of the early G1-phase inhibitor, p18 INK4C. Nature Cell Biol, 6(5): 436-442, 2004.
  • Myers TK, Andreuzza S, Franklin DS. p18 INK4c and p27KIP1 are required for cell cycle arrest of differentiated myotubes. Exp Cell Res, 300(2): 365-378, 2004.
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Back to the top

 

Our Partners

Information for Researchers
 
more info »
 

Latest News
 
more news »